FPA Crescent Loads Up on Cash
Manager Steven Romick has free rein to branch out, but hasn't seen anything compelling recently.
At FPA Crescent (symbol FPACX), manager Steven Romick can invest almost anywhere in the world and in nearly any kind of asset. That includes the standard fare — stocks, bonds and cash — and some not-so-typical investments, including currencies and subprime home loans.
But the fund’s unrestrained mandate doesn’t mean Romick takes undue risks. He’s a value investor who invests with a long view. “We seek the unloved, the out-of-favor or the misunderstood,” he says. His contrarian strategy, plus Crescent’s large exposure to assets other than stocks, means the fund will occasionally lag the broad stock market, especially when the market is roaring. Over the past year, for instance, Crescent trailed Standard & Poor’s 500-stock index by 4.3 percentage points. (By contrast, it beat the average balanced fund by 2.1 points.) But over the long haul, Crescent has shone: Since its 1993 launch, it has earned 11.0% annualized, outpacing the S&P 500 by an average of 2.4 percentage points per year. And it has done so with 35% less volatility than the index (results are through May 3).
Part of the problem, says Romick: “Nothing’s really attractive, so we’ve been on the sidelines.” He is not afraid to let cash build in the fund. At last report, about 32% of the fund’s assets sat in cash and other short-term investments.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
But Romick hasn’t been completely idle. He added to some existing holdings (including medical-equipment maker Thermo Fisher Scientific) and trimmed others (Wal-Mart Stores). And he’s finding attractive opportunities overseas, such as Norwegian food company Orkla. But, he says, the changes were “nothing substantial.”
Hedging some bets. Besides the cash hoard, Crescent recently had 62% of its assets in stocks, 2% in corporate bonds and 1% in mortgage bonds. The remaining 3%? That sat in stocks sold short (a bet on falling prices). Sometimes Romick will juxtapose a short sale with a business he likes. Take CVS, the drugstore chain. It’s one of Crescent’s best performers over the past year (up 29%). Romick liked CVS because of the firm’s drug-benefits unit, Caremark. To hedge his bet, he sold short shares of Express Scripts, a Caremark rival.
Lately, Romick has shown an activist streak, taking on the board of directors at Occidental Petroleum. He objected to the board’s plan to replace CEO Stephen Chazen. Under pressure from Romick and other Oxy shareholders, the board reversed course and agreed to let Chazen stay on until the end of 2014.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Nellie joined Kiplinger in August 2011 after a seven-year stint in Hong Kong. There, she worked for the Wall Street Journal Asia, where as lifestyle editor, she launched and edited Scene Asia, an online guide to food, wine, entertainment and the arts in Asia. Prior to that, she was an editor at Weekend Journal, the Friday lifestyle section of the Wall Street Journal Asia. Kiplinger isn't Nellie's first foray into personal finance: She has also worked at SmartMoney (rising from fact-checker to senior writer), and she was a senior editor at Money.
-
Stock Market Today: Stocks Rally Despite Rising Geopolitical Tension
The main indexes were mixed on Tuesday but closed well off their lows after an early flight to safety.
By David Dittman Published
-
What's at Stake for Alphabet as DOJ Eyes Google's Chrome
Alphabet is higher Tuesday even as antitrust officials at the DOJ support forcing Google to sell its popular web browser. Here's what you need to know.
By Joey Solitro Published
-
The 5 Best Actively Managed Fidelity Funds to Buy Now
mutual funds In a stock picker's market, it's sometimes best to leave the driving to the pros. These Fidelity funds provide investors solid active management at low costs.
By Kent Thune Last updated
-
The 12 Best Bear Market ETFs to Buy Now
ETFs Investors who are fearful about the more uncertainty in the new year can find plenty of protection among these bear market ETFs.
By Kyle Woodley Published
-
Don't Give Up on the Eurozone
mutual funds As Europe’s economy (and stock markets) wobble, Janus Henderson European Focus Fund (HFETX) keeps its footing with a focus on large Europe-based multinationals.
By Rivan V. Stinson Published
-
Best Bond Funds to Buy
Investing for Income The best bond funds provide investors with income and stability – and are worthy additions to any well-balanced portfolios.
By Jeff Reeves Last updated
-
Vanguard Global ESG Select Stock Profits from ESG Leaders
mutual funds Vanguard Global ESG Select Stock (VEIGX) favors firms with high standards for their businesses.
By Rivan V. Stinson Published
-
Kip ETF 20: What's In, What's Out and Why
Kip ETF 20 The broad market has taken a major hit so far in 2022, sparking some tactical changes to Kiplinger's lineup of the best low-cost ETFs.
By Nellie S. Huang Published
-
ETFs Are Now Mainstream. Here's Why They're So Appealing.
Investing for Income ETFs offer investors broad diversification to their portfolios and at low costs to boot.
By Nellie S. Huang Published
-
Do You Have Gun Stocks in Your Funds?
ESG Investors looking to make changes amid gun violence can easily divest from gun stocks ... though it's trickier if they own them through funds.
By Ellen Kennedy Published